Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
Clinical trial NCT04405674 · UNKNOWN
Trial details
- NCT number
- NCT04405674
- Sponsor
- Shanghai Chest Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-15
- Primary completion
- 2022-04-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.